Brain Matters Research

Running trials

• Recruiting

  AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  NCT07720271· Phase 3· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Source

• Recruiting

  Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

  NCT06847321· Phase 2· Source

• Active, not recruiting

  PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

  NCT06750432· Phase 1· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Source

• Recruiting

  Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

  NCT06584357· Source

• Active, not recruiting

  A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

  NCT06223360· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

  NCT06335173· Phase 2· Source

• Enrolling by invitation

  Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

  NCT06245031· Source

• Enrolling by invitation

  Alzheimer's Plasma Extension

  NCT06416072· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

  NCT05531656· Phase 2· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Source

• Active, not recruiting

  AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

  NCT04468659· Phase 3· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Source

• Active, not recruiting

  Multi-Center Study of Sensory Stimulation to Improve Brain Function

  NCT03556280· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease5 recruiting
• Lewy body dementia1 recruiting
• Obesity1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· Phase 2· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

  NCT06540833· Phase 2· Source

• Completed

  A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

  NCT05891496· Phase 3· Source

• Completed

  A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

  NCT05637801· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Terminated

  Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

  NCT05352763· Phase 2· Source

• Completed

  A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

  NCT05063539· Phase 2· Source

• Completed

  SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

  NCT04381468· Phase 1/2· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

  NCT04388254· Phase 2· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  TRC-PAD Program: In-Clinic Trial-Ready Cohort

  NCT04004767· Source

• Completed

  Memory Improvement Through Nicotine Dosing (MIND) Study

  NCT02720445· Phase 2· Source